Dataset: 11.1K articles from the COVID-19 Open Research Dataset (PMC Open Access subset)
All articles are made available under a Creative Commons or similar license. Specific licensing information for individual articles can be found in the PMC source and CORD-19 metadata.
More datasets: Wikipedia | CORD-19
Deep Learning Technology: Sebastian Arnold, Betty van Aken, Paul Grundmann, Felix A. Gers and Alexander Löser. Learning Contextualized Document Representations for Healthcare Answer Retrieval. The Web Conference 2020 (WWW'20)
Funded by The Federal Ministry for Economic Affairs and Energy; Grant: 01MD19013D, Smart-MD Project, Digital Technologies
Social and demographic contexts can significantly influence the transmission of infectious disease, while also creating increased vulnerabilities for some population subgroups. The elderly are at greater risk of many infectious diseases, and the ageing trend in many high-income countries could increase the challenges related to nosocomial (hospital-acquired) and nursing-home acquired infections. An additional challenge related to population ageing is that the share of employed workers in a country decreases. The combination of more people to care for and fewer tax-related revenues may challenge publicly financed public health and disease control programmes (7).
When persons from regions with high endemicity of a given disease move to ones with lower endemicity, new challenges for public health are created. In addition migrant communities can be highly vulnerable to certain infectious diseases. In the EU, for example, approximately 37% of HIV cases reported in 2011 were among people born abroad, and the equivalent number of cases for tuberculosis was 25% (40). Similarly, migrants suffer from a higher burden of chronic hepatitis B infections (41).
It is widely established that socially and economically disadvantaged groups suffer disproportionally from disease (42). This is applicable to infectious disease burdens in both high- and low-income settings (43, 44). Income inequalities are generally widening globally, and this appears to be have been exacerbated in many countries due to the global economic crisis (45). Rising unemployment and the prospect of public health budget cuts can increase the risk of infectious disease transmission (44, 46), with a prominent example being an outbreak of HIV among people who inject drugs (PWID) in Greece (see ‘Measles among Roma in Bulgaria and HIV among PWID in Greece: the impact of socioeconomic contexts’ section) (47, 48). In a similar fashion, it has been speculated that tuberculosis rates could rise in some countries in Central and Eastern Europe (49).
Social trends and behaviours can also play a significant role in infectious disease transmission. The most notable example would be vaccine hesitancy, the phenomenon through which vaccination coverage rates remain suboptimal due to the varying and complicated reasons that individuals may have for not getting vaccinated (50, 51). In some cases, this might be related to misconceptions about the safety or efficacy of vaccines (50, 52), whereas in others this may be related to religious or cultural beliefs (53).
The financing, provision, and quality of healthcare systems; the availability of vaccines, antivirals, and antibiotics medicines, and appropriate compliance to treatment protocols are all important determinants of infectious disease transmission. Although the correlation between healthcare system financing and efficacy is not perfect, recent budget cuts to healthcare are an important consideration when anticipating infectious disease risk. In part related to the global economic crisis, it has been reported that many high-income governments have introduced policies to lower spending through cutting the prices of medical products and, for example, through budget restrictions and wage cuts in hospitals (54). There are many indirect and direct pathways through which budget cuts could affect disease transmission; to provide just one example, it has been estimated that 20–30% of healthcare-associated infections are preventable with intensive hygiene and control programmes2 – should investments in this area diminish, then healthcare-acquired infections could become an even more problematic issue. There are currently roughly 4.1 million healthcare-associated infections each year in the EU alone.3
A broader issue related to healthcare provision is population mobility for both healthcare professionals and patients who might increasingly seek work or healthcare in other countries – the provision of cross-border healthcare and the mitigation of cross-border health threats will necessitate collaboration across borders (55, 56) and solutions for the brain-drain of medical personnel from resource-poor countries (57). Also related to the healthcare provision and practice is the over-prescription or overuse of antibiotics. In combination with a lag in pharmaceutical innovation, rapid transmission, and poor infection control measures, this has driven resistance of organisms such as methicillin-resistant Staphylococcus aureus, or extended-spectrum beta-lactamases, and carbapenemase-producing gram-negatives such as Klebsiella pneumoniae carbapenemase (KPC) (58). Antimicrobial resistance is currently one of the major health risks facing society (59).
Food production systems remain a persistent source for human infectious diseases. Attempts are underway to estimate the global burden of food-borne disease (60), which is likely substantial. Many factors in food production affect human health. A vast range of familiar human pathogens can be acquired through the consumption of animal products and other disease drivers, such as global travel, further provoke this (61). In addition to farmed animals, the hunting and slaughtering of wild animals has led to the emergence of more exotic pathogens: SARS originated in wildlife markets and restaurants in southern China (62) and HIV and Ebola have both been linked to the hunting or slaughtering of primates and other wild animals (33, 63, 64). The density and health of livestock, meanwhile, have been linked to disease in humans (65, 66). Although inconclusive, there is some evidence to suggest that livestock production may lead to increased antibiotic resistance in human pathogens. There are certainly many pathways by which drug resistant pathogens could transmit from livestock to humans, including environmental contamination by excreted veterinary antibiotics (33, 67, 68).
Emerging infectious diseases under this category were subcategorized into 1a, 1b and 1c. Subcategory 1a covers known pathogens that occur in new ecological niches/geographical areas. A few past examples belonging to this subcategory are the introduction and spread of West Nile virus in North America; chikungunya virus of the Central/East Africa genotype in Reunion Island, the Indian subcontinent and South East Asia; and dengue virus of different serotypes in the Pacific Islands and Central and South America.18,19,20,21,22,23 Factors that contributed to the occurrence of emerging infectious diseases in this subcategory include population growth; urbanization; environmental and anthropogenic driven ecological changes; increased volume and speed of international travel and commerce with rapid, massive movement of people, animals and commodities; and deterioration of public health infrastructure. Subcategory 1b includes known and unknown infectious agents that occur in new host ‘niches'. Infectious microbes/agents placed under this subcategory are better known as ‘opportunistic' pathogens that normally do not cause disease in immunocompetent human hosts but that can lead to serious diseases in immunocompromised individuals. The increased susceptibility of human hosts to infectious agents is largely due to the HIV/acquired immune deficiency syndrome pandemic, and to a lesser extent, due to immunosuppression resulting from cancer chemotherapy, anti-rejection treatments in transplant recipients, and drugs and monoclonal antibodies that are used to treat autoimmune and immune-mediated disorders. A notable example is the increased incidence of progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system that is caused by the polyomavirus ‘JC' following the increased use of immunomodulatory therapies for anti-rejection regimens and for the treatment of autoimmune diseases.24,25,26 Subcategory 1c includes known and unknown infectious agents causing infections associated with iatrogenic modalities. Some examples of emerging infections under this subcategory include therapeutic epidural injection of steroids that are contaminated with Exserhilum rostratum and infectious agents transmitted from donor to recipients through organ transplantation, such as rabies virus, West Nile virus, Dandenong virus or Acanthamoeba.27,28,29,30,31
Emergence and reemergence of infectious diseases occur over time. Prior to causing an epidemic, infectious disease agents go through various stages of adaptation to access or acquire pathogenic characteristics in a new host. Specific processes such as gene mutation, genetic recombination, or reassortment as well as factors that compel microbial agents to change reservoir hosts constitute opportunities for infectious agents to evolve, adapt to new hosts in new ecological niches, and spread easily [18, 19]. A number of factors contribute to this adaptation and consequent disease emergence. The complex interactions between infectious agents, hosts, and the environment are key.
Specifically, factors affecting the environment include depletion of forests, expansion and modernization of agricultural practices, and natural disasters such as floods. These potentially lead to changes in microbial ecological niches and fuel microbial adaptation to human host [20, 21]. Sociodemographic factors such as increase in population density, falling living standards, decline of infrastructure, human travel, conflicts and social instability, and killing of wild animals for meat all lead to increase in host-microbe contact, which facilitate infections in humans [22–25]. There are also some pathogens whose emergence is as a result of deliberate human action. These are those employed as biological weapons for destruction and so their emergence is “deliberate.”
Besides host and environmental factors, changes or mutation in the genome of a pathogen, which occurs as a result of exposure to chemicals and antimicrobial agents (e.g., antibiotic), may lead to gene damage and emergence of drug resistant pathogen variants that could cause new disease. Thus, human, microbial, and environmental factors constitute major causes of infectious disease emergence and the virulence or pathogenic potential depends on a complex combination of these factors. However, generally, emerging infectious diseases caused by viral pathogens are responsible for the greatest proportion of the EID threat, having caused about two-thirds of the infectious disease burden and usually characterized by very high epidemics. Examples are Filoviruses, Ebola, and Marburg [28, 29].
Examples of past emerging infectious diseases under this category are antimicrobial resistant microorganisms (e.g., Mycobacterium tuberculosis, Plasmodium falciparum, Staphylococcus aureus) and pandemic influenza due to a new subtype or strain of influenza A virus (e.g., influenza virus A/California/04/2009(H1N1)).9,32,33,34,35 Factors that contribute to the emergence of these novel phenotype pathogens are the abuse of antimicrobial drugs, ecological and host-driven microbial mixing, microbial mutations, genetic drift or re-assortment and environmental selection. Accidental or potentially intentional release of laboratory manipulated strains resulting in epidemics is included in this category.
Hepatitis B is found in virtually every region of the globe. Of the more than 2 billion people who are or have been infected, 350 to 400 million are carriers of the chronic disease; the remainder undergo spontaneous recovery and production of protective antibodies. Nearly 100% of infected infants (that is, those born to HBV-infected mothers) become chronically infected. The risk of developing a chronic infection decreases with age.
At least 30% of those with chronic HBV infection experience significant morbidity or mortality, including cirrhosis and hepatocellular carcinoma. Most people do not know they are infected until they present with symptoms of advanced liver disease, which means that infected individuals can spread the infection unknowingly, sometimes for many years. Although oral antiviral therapies are effective at stopping HBV replication, they do not cure the disease. Therefore, therapy is usually lifelong. Treatment is also complicated by the development of drug resistance and side effects. A vaccine against HBV is safe and effective in 90 to 95% of people; however, the individuals who are most at risk of becoming infected are often those with limited access to the vaccine, such as marginalized populations or people living in resource-limited countries.
There is substantial evidence that an individual's likelihood of recovering from an acute HBV infection or developing severe sequelae from infection is influenced, in part, by genes [39–45]. Candidate gene and genome-wide association studies have identified variants associated with HBV-related disease progression or hepatocellular carcinoma in various populations [46–52]. Treatment response to interferon (IFN)-α has been associated in some, but not all, studies with IFNλ3 polymorphisms. Finally, specific gene variants (HLA and non-HLA alleles) have been associated with vaccine response and non-response [54–57].
A “disease” is any condition that impairs the normal function of a body organ and/or system, of the psyche, or of the organism as a whole, which is associated with specific signs and symptoms. Factors that lead to organs and/or systems function impairment may be intrinsic or extrinsic. Intrinsic factors arise from within the host and may be due to the genetic features of an organism or any disorder within the host that interferes with normal functional processes of a body organ and/or system. An example is the genetic disease, sickle cell anaemia, characterized by pain leading to organ damage due to defect in haemoglobin of the red blood cell, which occurs as a result of change of a single base, thymine, to adenine in a gene responsible for encoding one of the protein chains of haemoglobin. Extrinsic factors are those that access the host's system when the host contacts an agent from outside. An example is the bite of a mosquito of Anopheles species that transmits the Plasmodium falciparum parasite, which causes malaria. A disease that occurs through the invasion of a host by a foreign agent whose activities harm or impair the normal functioning of the host's organs and/or systems is referred to as infectious disease [1–3].
Infectious diseases are generally caused by microorganisms. They derive their importance from the type and extent of damage their causative agents inflict on organs and/or systems when they gain entry into a host. Entry into host is mostly by routes such as the mouth, eyes, genital openings, nose, and the skin. Damage to tissues mainly results from the growth and metabolic processes of infectious agents intracellular or within body fluids, with the production and release of toxins or enzymes that interfere with the normal functions of organs and/or systems. These products may be distributed and cause damage in other organs and/or systems or function such that the pathogen consequently invades more organs and/or systems.
Naturally the host's elaborate defence mechanism, immune system, fights infectious agents and eliminates them. Infectious disease results or emerges in instances when the immune system fails to eliminate pathogenic infectious agents. Thus, all infectious diseases emerge at some point in time in a given population and in a given context or environment. By understanding the dynamics of disease and the means of contracting it, methods of fighting, preventing, and controlling are developed [2, 5, 6]. However, some pathogens, after apparent elimination and a period of dormancy, are able to acquire properties that enable them to reinfect their original or new hosts, usually in increasingly alarming proportions.
Understanding how once dominant diseases are reappearing is critical to controlling the damage they cause. The world is constantly faced with challenges from infectious diseases, some of which, though having pandemic potential, either receive less attention or are neglected. There is a need for constant awareness of infectious diseases and advances in control efforts to help engender appropriate public health responses [7, 8].
In 2008–2017, morbidity of Class B infectious diseases showed a significant downward trend, from 185.34/100,000 in 2008 to 54.36/100,000 in 2017 (χ2trend = 11,093.22, p < 0.05), with an annual morbidity of 90.39/100,000; morbidity of Class C infectious diseases showed a fluctuating upward trend, from 1352.97/100,000 in 2008 to 2549.03/100,000 in 2017 (χ2trend = 97,595.69, p < 0.05), with an average annual morbidity rate of 2412.47/100,000 (Table 1).
The top 5 reported Class B infectious diseases were dysentery, scarlet fever, measles, Influenza A (H1N1) and syphilis. The morbidity of measles, dysentery and syphilis showed a decline (measles: χ2trend = 10,156.59, p < 0.05; dysentery: χ2trend = 6301.75, p < 0.05; syphilis: χ2trend = 3376.99, p < 0.05); and that of scarlet fever was on the rise in recent years (χ2trend = 4185.20, p < 0.05). Influenza A (H1N1) was classified as a Class B infectious disease in 2009; 5805 cases of influenza A (H1N1) were reported in 2009, ranking first among Class B infectious diseases reported in the same year. This disease showed a decline in 2010 (χ2 = 5126.04, p < 0.05), and the number of cases reported was between 3 and 259 in 2010–2013. Since 1 January 2014, it was removed from Class B to Class C under the management of existing influenza (Figure 1).
The top 5 reported Class C infectious diseases were hand-foot-and-mouth disease (HFMD), other infectious diarrheal diseases, mumps, influenza and acute hemorrhagic conjunctivitis, among which the morbidity of HFMD, other infectious diarrheal diseases, and influenza were on the rise, while the morbidity of acute hemorrhagic conjunctivitis and mumps were decreasing year by year. In 2010, 11,789 cases of acute hemorrhagic conjunctivitis were reported, and thereafter the number of cases reported decreased rapidly (Figure 2).
Acute viral infections such as influenza also have profound impacts on global health. In contrast to the yearly epidemics caused by seasonal influenza, a pandemic can occur when a new virus emerges in a naive population and is readily transmitted from person to person. The US Centers for Disease Control (CDC) estimates that the H1N1 2009 pandemic resulted in 41 to 84 million infections, 183,000 to 378,000 hospitalizations, and nearly 285,000 deaths worldwide. Although the morbidity and mortality of that pandemic were lower than feared, public health professionals continuously monitor for the emergence of more virulent strains.
As an airborne infection, influenza is transmitted easily and quickly, and its effects can be acute, although there is wide variability in response to infection. Much of the heterogeneity in the severity of seasonal influenza infections has been attributed to the degree of acquired immunity in the population affected, patient co-morbidities and the virulence of the strain. Also, influenza epidemics and pandemics are often caused by the introduction of novel viruses for which most people have limited acquired immunity. The emergence of new strains, and the lack of cross-protection by existing vaccines, does not leave much time for vaccine development. In pandemics, including the H1N1 2009 influenza pandemic, healthy young individuals with no co-morbidities have comprised a significant proportion of fatal and severe cases. These pandemics have provided an opportunity to evaluate the host innate immune response among populations without underlying background immunity.
Research has identified genetic factors associated with severity of illness due to influenza [63–65] and death from severe influenza. Genetic information about immune response to influenza could inform vaccine development and distribution, and disease treatment strategies. Several candidate gene studies suggest that variations in HLA class 1 and other genes contribute to differences in antibody response to influenza vaccines. Ongoing experience with vaccine use has provided opportunities to learn about the potential role of genetics in vaccine safety and efficacy.
Data on entero-hemorrhagic E.coli infections has been collected since it was designated as a notifiable infectious disease in 2000. One case in 2000, 11 in 2001, and 8 in 2002 were reported, and the incidence has increased since 2003, when surveillance of hemolytic uremic syndrome was implemented and the monitoring was reinforced. Except for 118 cases in 2004, about 50 cases have been reported yearly (Fig. 2)5). Among the 58 cases reported in 2008, 32 cases were men and 26 women, indicating that there was no significant difference between genders, and 24 cases (41.4%) were reported between June and August6).
For the past decade, the total number of reported cases was 486 and patients aged <10 years and 10 to 19 years accounted for 59.9% (291 cases) and 14.2% (69 cases), respectively5).
In the following, we will compare the number of people infected and the total
cost of treatment in both cases to illustrate the impact of government
intervention. As we cannot obtain a specific analytical solution using the
calculation process mentioned above, the research process will obtain the
results through the numerical simulation process. Assuming the total number of
people to be Nt=1, that is, regardless of the new birth and death of the
population, St,It,Rt indicate the number of susceptible people, infected people,
and patients cured. Furthermore, we assume the number of effective contact.
Following is the numerical simulation of the number of infected persons in
different parameters, including 3 cases: high cost (α=10,μ=0), low cost (α=5,μ=0), and full subsidy (α=5,μ=5). Through comparative analysis of high-cost and low-cost
treatment, the impact of treatment cost on the evolution of infectious diseases
was obtained. The impact of government intervention on the evolution of
infectious diseases was captured by comparing the results between no subsidy and
full subsidy. (Due to limitations, this article only considers these 3
situations. Readers can use other parameters to practice numerical simulation,
such as partial subsidy case, but the basic rules and main conclusions will not
change.) The simulation results are shown in Figure 4; for more details on the
numerical simulation, please see the appendix.
From Figure 4, 2 important conclusions
can be drawn: first, the treatment cost of infectious diseases has a critical
influence on the evolution of infectious disease. Specifically, under the
condition of high cost and no government intervention (α=10,μ=0), even after 10 000 periods of time evolution, the proportion
of infected people still exceeds 50%, and the highest number of infected people
is close to 80%. At low cost, even without government intervention
(α=5,μ=0), the number of infected people will decrease rapidly over
time, but the maximum number of infected people will exceed 77%, and it will
take a very long period of time (1774 periods) to control the disease. In other
words, infectious will fall to zero or everyone is cured after 1774 periods.
Second, government intervention has an important impact on the evolution of
infectious diseases. If the government implements full subsidy for infectious
disease (without considering the impact of data costs under full subsidy), the
number of infected people will drop rapidly and will fall to zero in the eighth
period. Infectious diseases can be effectively controlled in a short period of
Morbidity of notifiable infectious diseases in China, represented by estimated numbers of new cases, declined substantially (>90%) from 22,000 cases per million in 1975 to a nadir level of 1,800 cases per million in 1995 (Figure 1a). Since then, the rate of new infectious disease cases gradually reverted and maintained an upward trend. In 2008, the estimated rate of infectious diseases among the general Chinese population reached over 3000 cases per million population. The composition of diagnosed diseases cases also changed substantially, in 1975, the three most reported diseases were gastrointestinal diseases (41.9%), vector-borne diseases (30.8%) and vaccine-preventable diseases (21.1%), corresponding to a total of 93.8% of all diagnosed cases (Figure 1a). Additionally, these three types of diseases account for 35.5, 21.7 and 18.4 million reported cases respectively during the period 1975–1979 (Table 1). In contrast, in 1995, although gastrointestinal diseases remained the dominating disease type (41.6%), the proportion of all cases that were due to viral hepatitis quickly rose to 35.7%. Sexually transmitted diseases re-emerged, and together with HIV, consisted of a substantial 6.3% of all reported cases. In 2008, the three most frequently reported disease types included viral hepatitis (38.3%), bacterial infections (33.3%) and STIs and HIV (9.8%), which account for 5.4, 4.8 and 1.4 million diagnosed cases respectively during the period 2005–2008 (Table 1).
Rapid declines in infectious diseases mortality and its similar saddle pattern were also observed in the past 35 years. The overall mortality rate in China decreased from 66 cases per million in 1975 to 5 cases per million in 1995, then it gradually reverted to 10 cases per million in 2008 (Figure 1b). Vaccine-preventable diseases, bacterial infections and gastrointestinal diseases were the greatest causes of death, accounting for 30.0%, 24.0% and 19.5% of reported infectious diseases death cases among Chinese population in 1975 (Figure 1b). However, the rank of composition shifted to zoonoses (22%), viral hepatitis (17.3%) and quarantinable diseases (15.3%) in 1995. Since then, the proportion of deaths caused by STIs and HIV, and bacterial infections rapidly increased. By 2008, STIs and HIV (39.5%) has become the mostly deadly infectious disease, followed by bacterial infections (24.7%) and zoonoses (20.0%). During the period 2005–2008, these three types of diseases have led to approximately 12,500, 13,300 and 11,400 deaths in China, respectively (Table 1).
Case fatality rate measures the percentage of deaths among people who contracted a disease. During 1975–2008, the disease type with the highest fatality rate is zoonoses, consistently causing 5–15% of deaths among the infected population. Following that, quarantinable diseases killed 1.4–5.6% of its infected population during the same period. In comparison, fatality rates in vaccine-preventable (0.112% during 2005–2008), gastrointestinal diseases (0.036%), bacterial infections (0.277%) and viral hepatitis (0.086%) show clear decreasing trends in China, corresponding to 3.5, 3.6, 12.4 and 2.4 folders reduction in comparison with the period 1975–1979, respectively. However, fatality of STIs and HIV increased to 0.894% during 2005–2008, doubling the level in 1985–1989 (Table 1).
During the period of 2008–2017, a total of 32 types and 1,994,740 cases of notifiable diseases in children aged 0–14 years, including 266 deaths, were reported in Zhejiang Province, with an annual average morbidity rate of 2502.87/100,000 and an annual average mortality rate of 0.33/100,000. There were no cases and deaths involving plague, cholera, infectious atypical pneumonia, human infection with avian influenza, polio, anthrax, diphtheria and filariasis. No Class A infectious diseases were reported. Twenty-two types and 72,041 cases of Class B infectious diseases were reported, including 138 deaths; 10 types and 1,922,699 cases of Class C infectious diseases were reported, including 128 deaths.
Currently, 39 infectious diseases are notifiable in China, classified as A, B or C according to their epidemic levels and potential population threats. Groups A and B (total 28 diseases) represent categories of diseases with high risk of outbreaks or that are likely to result in rapid spread once an outbreak occurs. Mortality and morbidity related to group A and B diseases are reported and published by the Chinese Ministry of Health on a monthly basis. Group C diseases are less infectious and, when outbreaks occur, are epidemiologically less severe. They are required to be reported only when outbreaks occur.
In this review, we searched published peer-reviewed research articles as well as online reports and grey literature from 1985 to 2010 relevant to disease surveillance in China in the following databases: PubMed, Chinese Scientific Journals Fulltext Database (CQVIP), China National Knowledge Infrastructure (CNKI) and Wanfang Data. Keywords used in the database search included [‘Chinese’ or ‘China’] and [‘Infectious diseases surveillance’ or ‘surveillance system’ or ‘infectious diseases monitoring’ or ‘infectious diseases information’ or the type of infectious disease or the name of individual infectious diseases]. We also searched governmental reports, reports of non-governmental organisations and other grey literature from online sources. We then collated data on notified cases and mortality related to these diseases, using the latest available information from the Ministry of Health. Notifiable infectious disease data, including morbidity and mortality rates, was summarised by Chinese Ministry of Health and published annually in Chinese Health Yearbook and online accessible through CNKI database. Notably, this dataset does not contain data on SARS and influenza A(H5N1) virus infection. Hence we did not include them in our statistical analysis, but describe them in the text.
The selected diseases were categorised into eight major types according to their diseases characteristics and origins. The morbidity and mortality for each disease type were calculated as the sum of the corresponding rates of individual diseases. The total number of diagnosed and death cases were estimated by multiplying morbidity and mortality rates by the overall Chinese population in the study years. Case fatality rate was defined as the percentage of persons diagnosed with the disease who die as a result of the illness during the calendar year, and was estimated by dividing mortality rate by morbidity rate of the diseases. Further, for each individual disease, we calculate the disease-specific mortality rates among the Chinese population in five-year intervals (1999–2003 and 2004–2008). For each disease, the mean annual increase or decrease during 1999–2008, with 95% confidence intervals, is estimated, based on linear regression of logarithmic values of the number of annual death cases.
Hepatitis A was included in category I notifiable infectious diseases under the "Law for Control and Prevention of Infectious Diseases" in the version revised on December 30, 20102). Since hepatitis A was officially followed up from 2001, exact data enabling us to examine the previous incidence do not exist. However, according to a published report7), among all patients who had been hospitalized in the department of pediatrics over 10 years from 1968 to 1977, patients with hepatitis A accounted for 2.5% (1.7 to 3.9%) on the average. A similar trend continued until the early 1980s, and sharply decreased thereafter, and increased again in 19968).
According to the sentinel surveillance system started from 2001, hepatitis A incidence showed a sharply increasing trends for several years, with less than 400 cases in 2001 to 2004, about 800 in 2005, 2,000 in 2006 to 2007, 7,900 in 2008, and 15,000 in 2009, and then tended to decrease from 2010 with 7,700 cases5) (Table 2), but the actual incidence is expected to be several folds higher8). Moreover, there was huge difference in incidence between regions, such that the incidence was 75 to 80% in Seoul, Gyeonggido and Incheon areas but the incidence was much lower in Gyeongsangbukdo and Gyeongsangnamdo areas, including Daegu and Busan5).
Regarding the age of cases, most occurrences were reported in patients in their 10s and 20s, and few cases occurred in patients in their 30s in 1990s. However, most occurrences during 2001 to 2007 were reported in patients in their 20s, followed by those in their 30s and 10s, and the order of the ages of occurrence was the 30s, 20s, 40s, and 10s after 20085).
Hepatitis A vaccine has still not been included in the national immunization program, but since its first use in the end of 1997, it is currently expected to be vaccinated in about 70% of infants and toddlers.
Assume the number of population to be N in this group, including susceptibles, infected, and healers,
which are denoted as S, I, and R, respectively. The average effective contact (transferable) with
other people for a person in a unit time is β; the number of people who are cured within the unit time is
γ; the treatment cost is α; and the government compensation is µμ. In reality, the number of patients or the number of people
participating in the treatment depends on the treatment cost. To encourage infected
patients to take treatment promptly, the government should provide moderate
compensation. Furthermore, suppose γ=e−α+μ in this study and obviously γ∈(0,1]. As the cost of treatment increases, the number of people
participating in treatment decreases, but government financial compensation can
effectively promote the participation of infected patients in treatment. According
to the model proposed by Kermack et al in 1927, and based on China’s successful
experience in dealing with SARS, this article establishes the compensation model for
important infectious diseases as follows:
Functions (1) to (3) meet the constraint S(t)+I(t)+R(t)=N. Compared with the traditional infectious disease models, this
model analyzes treatment costs and the impact of government interventions on
infectious diseases. Different from the traditional infectious disease models, the
above model considers the impact of government intervention on infectious diseases.
According to function (3), we know that government intervention will significantly
increase the population of the cured individuals, thereby reducing the spread speed
among the infected population.
Table 1 and figure 3 show 10 year trends in incidence of, and deaths from, each notifiable infectious disease by disease category, as well as the relative ranking (see fig 4 and supplementary figures S4-S6). Overall, three categories—vaccine preventable diseases, gastrointestinal and enterovirus diseases, and bacterial infections—still had high endemic levels. Among the other four categories with relatively low levels, sexually transmitted diseases and bloodborne infections increased noticeably.
Quarantinable diseases—among the three quarantinable diseases, cholera and plague had virtually disappeared. Haemorrhagic fever maintained a low but stable incidence (P=0.68).
Vaccine preventable diseases—the incidence of most vaccine preventable diseases decreased to low levels over the study period, particularly for rubella, measles, hepatitis A, and hepatitis B. For example, rubella dropped from third ranking to 17th and measles from eighth to 18th, and measles showed a 62.4% annual average decline from 2008 to 2011 (P=0.004 from 2008 to 2011), remaining low (P=0.61 from 2011 to 2017). The incidence of hepatitis A decreased from 6.1 to 0.4 per 100 000 and hepatitis B from 47.4 to 5.81 per 100 000, with 26.0% and 21.9% annual average declines, respectively (P<0.001). Pertussis incidence remained at a low level, and one joinpoint was identified in 2012. The incidence of pertussis decreased noticeably, with −21.5% APC (P=0.02) before 2012, but increased sharply from 2012 to 2017 with 36.1% APC (P<0.001). The incidence of mumps and seasonal influenza remained high, making these the most common vaccine preventable diseases in 2017. The relative increase of mumps and seasonal influenza accounted for 79.8% of the overall rebound between 2015 and 2017, especially for seasonal influenza, which showed 77.2% annual average increases across these two years (P=0.04). During 10 years, the incidence of seasonal influenza increased nearly 10-fold, from 6.3 per 100 000 in 2008 to 58.3 per 100 000 in 2017, an average annual 31.7% relative increase (P<0.001). No cases of diphtheria, neonatal tetanus, and poliomyelitis were recorded, and the mortality from vaccine preventable diseases was low.
Gastrointestinal and enterovirus diseases—a steady decline occurred in gastrointestinal and enterovirus diseases, including dysentery, acute haemorrhagic conjunctivitis, and typhoid and paratyphoid, with annual average declines of 13.4% (P<0.001), 33.9% (P=0.06), and 10.1% (P=0.001), respectively. However, noticeable relative increases occurred in incident cases of hand, foot, and mouth disease and infectious diarrhoea. The incidence of hand, foot, and mouth disease increased from 9.4 to 29.5 per 100 000, with an 8.6% annual average relative increase (P=0.04). A stable trend for infectious diarrhoea was observed from 2008 to 2014 (P=0.88), but a significant increase in incidence was found over the following four years, from 22.2 per 100 000 in 2014 to 34.0 per 100 000 in 2017 (APC=14.5%, P=0.03).
Vectorborne diseases—vectorborne diseases generally declined, with a particularly noticeable relative reduction in malaria, from 1.4 per 100 000 in 2008 to 0.012 per 100 000 in 2017 (APC=−40.6%, P=0.003, with a fall in ranking from 13th to 28th across the 10 year period). Sharp declines occurred across the first six years (APC=−63.4%, P<0.001), remaining stable until 2017 (P=0.83). The incidence of Japanese encephalitis, typhus, and Kala-azar steadily declined from 2008 to 2017 (APC=13.7%, P=0.001; 13.1%, P<0.001; and 16.0%, P<0.001, respectively). Among all the vectorborne diseases, Japanese encephalitis had the highest mortality, but it also showed a steady decline. Excluding the influence of a small outbreak in 2015, the incidence of schistosomiasis steadily declined across the 10 years (APC=−32.1%, P<0.001). The incidence of dengue increased from 0.009 per 100 000 in 2008 to 0.19 per 100 000 in 2017, a 20-fold relative increase across the decade, despite a small outbreak in 2014, with an incidence of 1.6 per 100 000.
Zoonotic infections—the incidence of all zoonotic infections was low. Rabies remained the second most common infectious cause of death overall, despite a decline in incidence of around 90% and annual average declines of 20.0% over the past decade (P<0.001). Steady declines were observed in hepatitis E and leptospirosis (P=0.001 and P<0.001, respectively), but brucellosis showed a significant increase, with annual average changes of 7.5% from 2008 to 2017 (P=0.04). Hydatid disease and anthrax maintained stable trends across the decade (P=0.33 and P=0.25, respectively), although a joinpoint year was identified in 2014 for hydatid disease in males, after which its incidence increased noticeably to 2017 (APC=38.1%, P=0.05). Hydatid disease remained stable in females. Similarly, a joinpoint year was identified in 2011 for anthrax, with a significant reduction from 2008 to 2011 (APC=−33.4%, P=0.05), followed by a stable trend to 2017 (P=0.27). An outbreak of H1N1 occurred in 2009, and an occasional emergence of other avian influenza across the decade, including H7N9 and H5N1.
Bacterial infections—overall, 2010 was identified as a turning point in trend for bacterial infections. The total incidence of bacterial infections decreased from 34.7 per 100 000 in 2008 to 24.6 per 100 000 in 2010 (APC=−14.3%, P=0.29), but then increased to 31.3 per 100 000 in 2017 (relative APC=2.1%, P=0.31, 2010-17). Significant declines were shown for tuberculosis, from 28.9 to 18.9 per 100 000, and for meningococcal meningitis, from 0.2 to 0.03 per 100 000, with relative APC reductions of 5.1% and 20.5%, respectively (P<0.001). Although the incidence of leprosy also showed a large decline, from 0.017 to 0.008 per 100 000, the APC of 7.3% was statistically insignificant. In contrast, the incidence of scarlet fever more than doubled, increasing from 5.6 to 12.4 per 100 000 across the 10 years, which increased its ranking from 11th in 2008 to sixth in 2017 (APC=10.1%, P=0.02).
Sexually transmitted diseases and bloodborne infections—2011 was identified as the turning point in trend for sexually transmitted disease and bloodborne infections over the decade. Total incidence decreased from 2.8 per 100 000 in 2008 to 2.3 per 100 000 in 2011 (APC=−5.4%, P=0.19), but then increased relatively to 3.7 per 100 000 in 2017, with a relative APC of 7.3% (P=0.002, 2011-17). Among four sexually transmitted diseases and bloodborne infections, the incidence of hepatitis C declined by about 63% over the study period, from 0.89 per 100 000 in 2008 to 0.33 per 100 000 in 2017 (APC=−11.8%, P<0.001). Cases of HIV/AIDS increased fivefold, from 0.27 per 100 000 in 2008 to 1.49 per 100 000 in 2017, with a large significant APC increase during the study period (APC=21.9%, P<0.001). HIV/AIDS incidence increased rapidly between 2008 and 2015 (APC=29.2%, P<0.001), with stable incidence reported from 2015 to 2017 (P=0.94). HIV/AIDS is now the major cause of death from infectious diseases in children and adolescents, having surpassed rabies in 2014. The incidence of syphilis steadily increased from 0.65 per 100 000 in 2008 to 0.99 per 100 000 in 2017, with a significant relative APC of 3.8% (P=0.004). Although the incidence of gonorrhoea was stable across the study period, one joinpoint was identified in 2012, with a large annual average decline of 22.4% from 2008 to 2012 (P=0.002). This was followed by a significant increase in the relative APC to 2017 (18.9%, P=0.004), with the incidence in 2017 (0.93 per 100 000) returning to 2008 levels (0.96 per 100 000).
From 2008 to 2017, China achieved impressive reductions in the burden from infectious diseases in children and adolescents aged 6 to 22 years. This complements the reduction in mortality from infectious diseases in under 5s—a longstanding focus of the Millennium Development Goals, and will contribute to reductions in the overall burden from infectious diseases in China.16
60 However, China’s rapid success poses challenges for policy makers as priorities for infectious disease control continue to evolve. Beyond maintaining the gains, the priorities for the coming decade include reducing regional inequalities; scaling-up vaccination for mumps, seasonal influenza, and hepatitis B; preventing further escalation of HIV/AIDS and other sexually transmitted diseases; and redoubling efforts around persisting diseases, including tuberculosis, rabies, and scarlet fever. Different responses will be needed by region and by age across childhood and adolescence, while the newer emerging disease epidemics will require rapid and targeted responses. Seasonal variation in respiratory infections and in gastrointestinal and enterovirus diseases reflect the high vulnerability of children and adolescents. A comprehensive national surveillance system remains an integral part of infectious disease control in these age groups to maintain the gains of recent decades and respond effectively to new epidemics.
In China, if a notifiable infectious disease is clinically diagnosed and/or laboratory confirmed according to the unified national diagnostic criteria issued by the NHFPC, cases must be reported to the national China CDC, which collects and analyses the acquired data. The health care provider enters the case information using a standard form into the Notifiable Infectious Diseases Reporting Information System (NIDRIS), a web-based system that enables all healthcare institutions to report cases of notifiable infectious diseases. Approximately 5 million infectious disease cases are reported annually (≈ 385 cases per 100,000 citizens per year). Each China CDC level can analyse its own data in NIDRIS and data from subordinate levels within its own administrative boundaries.
In the Netherlands, if a notifiable infectious disease is suspected and/or laboratory tests confirms it, the case must be reported both by the attending physician and the laboratory to the regional PHS. The case information is collected and entered by the PHS into Osiris, a web-based database that transmits the data to RIVM for further analyses. In 2014, 13,863 notifiable disease cases were reported via Osiris to RIVM (≈ 815 cases per 100,000 citizen per year).
Only puppies between 1 week to 4 months of age submitted for routine autopsy evaluation at the Laboratory of Animal Pathology, Veterinary Teaching Hospital, Universidade Estadual de Londrina, Southern Brazil to determine the cause of death by their owners between January 2013 to December 2017 were included. All autopsies and histopathologic findings were done by veterinary pathology residents (n = 7) under the supervision of two animal pathologists. These animals originated from several cities within the State of Paraná, Southern Brazil. The biological data of the puppies are given in Table 1; all data relative to breed, gender, age, clinical manifestation, and pathologic findings from autopsy reports were reviewed and tabulated. The owners of all dogs agreed to have the death of these animals investigated and consented to the usage of the results for scientific purposes.
The results from these findings have demonstrated that most puppies (80%; 12/15) submitted for routine autopsy were infected by two or more infectious disease pathogens. These results are similar to those described in other studies that examined one5,8,10,13,17,20,21,35 or more dogs7,18,19,24,25, to identify infectious disease pathogens by using several diagnostic methods. The location (cytoplasmic or nuclear) for the labelling of the antigens for all infectious disease pathogens observed during this study is consistent with previous studies26,36. During this investigation, 60% (9/15) of the puppies demonstrated triple or quadruple infectious diseases; similar results were described in a population of German Spitz puppies18, while a 45-day-old puppy was infected by five pathogens10, and triple viral infections were diagnosed in dogs from Mexico by IHC26. These findings suggest that concomitant infectious diseases in dogs, principally in puppies, as observed in this and other studies8,10,12,21,22,26 may be more frequent than previously described, and can result in sudden death, as occurred in all puppies from this study, probably due to multiple organs failure10. Although this study was focused on the identification of traditional infectious disease pathogens of dogs, it cannot be ignored that the possibility exists of the occurrence of additional infections associated with emerging19,37 infectious disease agents.
Nevertheless, this is one of the few studies that have associated traditional infectious disease pathogens of dogs with their respective histopathologic patterns and the intralesional identification by IHC; this strategy was used to identify several infectious disease pathogens in puppies8,11,26,38. This methodology has the advantage of confirming the participation of infectious disease agents in the development of disease processes, since tissue antigens are easily observed within histological sections39. Alternatively, other investigations have used several methods to associate the participation of pathogens with disease in dogs, including the exclusive identification of characteristic histopathologic findings5,7, histopathology with electron microscopy20, genotyping35, and with the IHC identification of associated pathogens21,26,38, or histopathology with molecular testing10,12, and in situ hybridization, ISH12,27. Moreover, these investigations have identified the presence of infectious disease pathogens using molecular techniques in symptomatic9,23,24, or asymptomatic19 dogs. Although there are advantages and disadvantages with the utilization of diagnostic IHC40, this method is recommended for the identification of intralesional antigens of infectious disease agents in Formalin-fixed paraffin embedded (FFPE) tissue sections36,39,41, and has been used extensively in veterinary medicine39. Additionally, immunohistochemistry, ISH, and electron microscopy, unlike molecular identification methods, clearly demonstrates the active participation of the infectious disease agent in the development of the disease process, while the molecular identification of disease pathogens does not necessarily imply that the identified pathogen is the cause of the associated disease process42.
All puppies investigated during this study contained CDV RNA as detected by RT-PCR, while antigens of CDV were observed in multiple tissues of most puppies. These findings demonstrated the disseminated tropism of CDV for epithelia and its capacity to induce clinical disease with associated histopathologic alterations in multiple tissues. The concomitant infections identified in most puppies can be attributed to the immunodepressive effects of this virus3,4, associated with the immature immunological system of these puppies, which facilitated the development of simultaneous infections in the same puppy. The immunodepressive effects associated with infections induced by CDV is associated with the selective destruction or impairment of cells that express the signalling lymphocyte activation molecule (SLAM, CD150) due to tropism for lymphoid tissues4. Moreover, experimental studies have demonstrated that in cases of fatal CDV-induced infections, as occurred during this study, there are reduced gene expressions of interferon gamma (IFN-γ) and interleukin-4 (IL-4)43. Collectively, reduced expression of cytokines (IFN-γ and IL-4) and downregulation of CD150 cells may be the key to understand the immunodepressive effects of CDV.
Antigens of CDV were identified within the epithelial cells of the lungs in all puppies with a histopathologic diagnosis of interstitial pneumonia, while in some of these cases there was the concomitant positive immunolabelling of antigens of CAdV-1 and -2; similar findings were described7,21,26. These results suggest that these two viral agents are also associated with interstitial pneumonia in dogs, and not only with CIRD2,34. Most cases of white matter demyelination of the cerebellum during this investigation contained CDV-positive astrocytes; similar findings were described11,38, indicating that these puppies were in the initial phase of neurological distemper in progression to develop canine distemper encephalitis, CDE2,3,44. These findings indicate that demyelination continues to be an important histopathologic lesion of neurological distemper2,3,15, with the cerebellum being the tissue of choice for the histopathologic diagnosis of CDE in immature dogs, since this neuroanatomical location is frequently affected in CDE2,44.
Positive immunolabelling for antigens of CAdV-1 were observed predominantly in hepatocytes and Kupffer cells of puppies with a histopathologic diagnosis of necrohaemorrhagic hepatitis and to a lesser extent in cases of interstitial pneumonia; similar findings have been described in ICH10,45–48. Additionally, gallbladder oedema was observed during the autopsy of several of these puppies during this investigation, as well as in other studies20,45,46. Moreover, the “blue eye” phenomenon and gallbladder oedema observed in one puppy are considered as typical clinical findings associated with CAdV-130,33,49,50. Intriguingly, positive immunolabelling to CAdV-1 was observed within hepatocytes and/or Kupffer cells but not at the oedematous epithelium of the gallbladder in any of these cases, while there was positive immunoreactivity to CDV at the oedematous gallbladder in one of these puppies. These findings might suggest that gallbladder oedema in ICH is not a direct viral-induced lesion but may be associated with CAdV-1 related haemodynamic alterations that are characteristic of this disease30,49, resulting in oedema to the gallbladder but without IHC evidence of this viral pathogen. However, the absence of positive IHC detection of CAdV-1 antigens in these cases can also be related to the clearance of the virus from the gallbladder and be time dependent, since infected dogs develops effective antibody response resulting in virus clearance from the liver seven days post-infection30. The authors have not located any manuscript that described this association, so these results are unique and add to the understanding of this important disease of dogs. In addition, the positive labelling of CDV at the oedematous epithelium of the gallbladder may simply represent the widespread tropism of this virus for epithelia and not directly related to the development of oedema at this or any other location.
This is one of the few investigations that have evaluated the histopathologic and immunohistochemical features of the “blue eye” phenomenon of ICH in modern diagnostic veterinary pathology, and adds to the excellent experimental studies that described the histopathologic features of the ocular disease in the 1960s31,32 with emphasis in Afghan hounds51, experimental confirmation of the type III hypersensitivity lesions52, and a review of this unique lesion50. This ocular lesion is traditionally considered and accepted as a type III hypersensitivity reaction of CAdV-130–32,50,53, and occurs in 20% of recovered puppies after 2–3 weeks of being infected31,32,53. However, in the case herein descried (puppy #15) as well as the eye from a previous study10, there was oedema of the corneal stroma with disruption of the anterior corneal epithelium and the Descemet’s membrane; these lesions were previously described in experimentally induced CAdV-1 infection puppies in which where there were accumulations of neutrophils, mononuclear inflammatory cells31,32,51, and fibrinous exudation31,32, frequently resulting in uveitis and interstitial keratitis31,32. However, in the cases herein described, moderate inflammatory reactions were restricted to the conjunctiva of puppy #15 and not observed in any anatomical region of the eye of a puppy from a previous study10. Alternatively, degenerative alterations to the corneal epithelium were not described in the experimentally induced ocular disease31,32,52. Furthermore, the post-infection period of the occurrence of corneal oedema in ICH seems to coincide with the initial manifestations of hepatocelular necrosis30,49. However, in puppy #15 with the “blue eye” phenomena, hepatocellular swelling (hydropic degeneration) and not hepatocellular necrosis was the predominant histopathologic pattern with positive immunoreactivity observed only within epithelial cells of bile ducts. While in puppy #16, there was necrohaemorrhagic hepatitis associated with intranuclear inclusion bodies characteristic of CAdV-1, with the hepatic disease being further aggravated due to the concomitant presence of intralesional cysts of T. gondii10. Additionally, the hepatocellular alteration as observed in puppy #15 is frequently described in ICH49, and may be associated with reduction in levels of blood glucose33. Consequently, it is proposed that CAdV-1 should be considered as a possible cause of hepatocellular degenerative lesions in puppies, principally those that have died after an acute onset of clinical manifestations.
Collectively, these findings may suggest that the histopathologic features of the ocular lesions associated with CAdV-1 seem to be predominantly degenerative in the spontaneous disease herein described and inflammatory in experimental-induced infections. Although the differences in histopathologic findings observed between the spontaneous ocular disease and the experimentally induced lesions32,52,54 are not fully known, we postulate that these differences might have occurred due to several factors. Firstly, they may be related to the routes of inoculation in the experimental studies; being subcutaneous and intravascular31,51 or intraocular32,52, as compared to the oronasal exposure in the natural disease. Secondly, the post-inoculation observation period of 2–3 weeks31 relative to the one week after initial manifestation of disease in the spontaneous disease can also contribute to these histopathologic differences. Furthermore, these time-based differences can be related to the pattern of histopathologic lesion observed in ICH. The hepatic pattern observed in puppy #15 was degenerative and not necrotic, and may probably represent an initial manifestation of hepatocellular injury induced by CAdV-1, since hepatocelular degeneration is commonly observed in ICH49, and antigens of CAdV-1 were identified in another puppy with this pattern of hepatic injury. Thirdly, the viral load used in the experimentally induced infectious studies might have been significantly elevated when compared to that of the spontaneous exposure of susceptible puppies to CAdV-1. Notwithstanding the above findings, two inflammatory phases of the CAdV-1 associated ocular disease were proposed50,52,55: the first is considered as a subclinical/clinical infection that is characterized principally by oedema with mononuclear accumulations and occurs at the anterior uvea, while the second is predominantly manifested by corneal oedema with histopathologic lesions indicative of type III hypersensitivity and results in keratouveitis. However, these phases are based on the results of experimental induced studies and not on the spontaneous occurrence of this unique ocular disease. Nevertheless, additional spontaneous cases of the “blue eye” phenomenon are required to efficiently characterize and understand the histopathologic findings of the ocular lesions in puppies naturally infected by CAdV-1.
Intralesional cysts that were immunoreactive to N. caninum but without positive immunolabelling for T. gondii were observed in multiple tissues of one puppy, indicating disseminated canine neosporosis56,57. In this case, the puppy did not demonstrate clinical manifestations suggestive of muscular disease; therefore, canine toxoplasmosis and not neosporosis was suspected, since T. gondii is frequently identified in dogs infected by CDV9,10. This puppy contained CDV RNA by RT-PCR, with additional positive immunolabelling for CDV, CAdV-2 and CPV-2, resulting in a quadruple infection; five infectious disease agents including T. gondii and CDV were diagnosed in puppy10. Moreover, coinfections of Leishmania chagasi, N. caninum, and T. gondii have been investigated in dogs, where it was suggested that the immunodepressive effects of L. chagasi might have influenced infections by N. caninum and T. gondii58. Therefore, one wonders if the known immunodepressive effects of CDV4 might have favoured the development of the protozoan infection in this puppy. This case represents one of the few documented reports of coinfections involving CDV and N. caninum in dogs. A clinical study demonstrated seropositivity to N. caninum in a dog with neurological manifestations and the simultaneous molecular identification of CDV nucleic acid9. Nevertheless, additional studies confirming concomitant infections involving these two infectious disease agents are required to efficiently evaluate this intriguing relationship.
Infections due to CAdV-2 are more frequently associated with CIRD2,34, while the occurrence of the spontaneous disease is rare in non-immunosuppressed dogs2. During this study, antigens of CAdV-2 were identified in the bronchiolar epithelium of puppies with interstitial pneumonia and CIRD, as well as in the liver of puppies with a histopathologic diagnosis of necrohaemorrhagic hepatitis and hepatocellular degeneration; similar findings were observed by ISH in puppies with interstitial pneumonia but without necrotizing bronchiolitis27 and by IHC in dogs with pneumonia26. However, we have not located a previous description of the intrahepatocellular localization and intestinal of CAdV-2 in dogs; disseminated infections involving the brain, lung, spleen and with ISH signals in Kupffer cells but not hepatocytes associated with CAdV-2 have been described in dogs with neurological manifestations27. These findings suggest that CAdV-2 can be associated with extra-pulmonary disease and that the occurrence of this pathogen should be investigated in multiple tissue of dogs. Additionally, the widespread identification of CAdV-2 in multiple organs and in several puppies can be associated with the immunosuppressive effects of CDV2, since all puppies were simultaneously infected by both pathogens.
The findings associated with infections due to CPV-2 in these puppies were similar to those described1,10,18,59 without any unusual pathologic or immunohistochemical observation, and suggest that CPV-2 should always be included in the differential diagnosis of puppies with a clinical history of haemorrhagic enteritis. Additionally, antigens of CDV, CAdV-2 and intralesional cysts of N. caninum were also identified concomitantly within the intestine in some of these puppies with haemorrhagic enteritis, suggesting that these infectious disease agents should also be included in the differential diagnoses of puppies with clinical histories of bloody diarrhoea. This is supported by the identification of antigens of CDV and not CPV-2 by IHC in the intestinal of with a puppy cryptal necrosis38, since CDV also produces enteric disease2,14.
During this study purebred dogs were overrepresented when compared to their mixed breed counterparts and may be a simple representation of the interest of their owners in determining the cause of death in these cases. However, when the head conformation of purebred dogs was analysed, brachycephalic breeds were more frequently affected relative to dolichocephalic dogs; similar findings were described in an epidemiological study of 250 dogs naturally infected by CDV16. Moreover, it was proposed that brachycephalic breeds are more predisposed to develop CD60, other neurological disorders, ocular and facial dysfunctions61 when compared to dolichocephalic dogs. Although the actual reason for this breed predisposition to develop diseases has not been fully elucidated, phenotypical head conformations of brachycephalic dogs was suggested as a possible reason due to differences in the orientation of the olfactory bulb in these specific breeds of dogs61. Additionally, dysfunctions to the olfactory bulb have been associated with the development of neurodegenerative diseases in humans due to the accumulations of pathologic proteins, α-synuclein, and neurofilament protein in the affected areas62. Consequently, it can be theorized that brachycephalic breeds of dogs are more likely to develop neurological disease, including CD, relative to their dolichocephalic counterparts, due to predisposed genetic confirmations at the olfactory bulb. Nevertheless, studies are needed to confirm the possible existence of histological differences at the olfactory bulb of brachycephalic and dolichocephalic breeds of dogs.
In conclusion, multiple infections by the viral agents herein described are common and more frequent than previously described and may result in the sudden death of puppies. Canine morbillivirus (CDV) continues to be one of the most important infectious disease agents of puppies and due to its immunosuppressive effects can facilitate the development of other infectious disease pathogens. The histopathologic pattern observed in the spontaneous cases of the “blue eye” phenomenon associated with infection by CAdV-1 in ICH was predominantly degenerative in nature. Antigens of CAdV-1 were not detected in association with gallbladder oedema in multiple animals from this study. Hepatocellular degeneration may be an initial degenerative phase of infections associated with CAdV-1, particularly in puppies that died suddenly. Interstitial pneumonia in dogs should be associated with multiple viral infectious disease pathogens, and several infectious disease pathogens must be included in the differential diagnosis during the investigation of the cause of death in puppies.
Although lower respiratory infections, including pneumonia, are one of the main causes of death worldwide, real-time surveillance systems and situational awareness are generally lacking.
In the year after the SARS outbreak in 2003, NHFPC developed a surveillance system for unexplained pneumonia to facilitate timely detection of airborne pathogens that form a severe threat to public health. Therefore, all Chinese health care facilities are required to report any patient who has a clinical diagnosis of pneumonia with an unknown causative pathogen and whose illness meets the following five criteria (2007 modified definition): (1) fever ≥38 °C; (2) radiologic characteristics consistent with pneumonia; (3) normal or reduced leukocyte count or low lymphocyte count in early clinical stage; (4) no improvement or worsening of the patient’s condition after first-line antibiotic treatment for 3–5 days; and (5) the pneumonia etiology cannot be attributed to an alternative laboratory or clinical diagnosis (clinicians are granted flexibility to determine how to interpret this criterion and specific tests are not specified) [22, 23]. Once the case is registered in NIDRIS, the data are further analysed in CIDARS as a type 1 disease, for which a fixed-threshold method (of 1 case) is applied. A real-time SMS is followed by a field investigation, whereby case samples are tested to rule out avian influenza, SARS and Middle East respiratory syndrome coronavirus (MERS-CoV). Although physicians are required to report unexplained pneumonia cases, considerable under-reporting occurs. The aim of this surveillance system is not to detect each unexplained pneumonia case but to focus on clusters that could indicate an (unknown) emerging infectious disease outbreak.
Unexplained pneumonia is not a notifiable condition in the Netherlands as it is in China. However, according to the Public Health Act (2008), each physician should notify a case or an unusual number of cases with an (unknown) infectious disease that forms a severe threat to public health. An example is the Q fever outbreak (2007); the unusual number of atypical pneumonia cases early in the outbreak were not detected by routine surveillance systems but by astute general practitioners (GPs). Both Dutch legislation and the Chinese pneumonia surveillance system aim for early notification of (unknown) emerging infectious disease outbreaks. However, in both countries, criteria for notification are not well defined and a considerable degree of under-ascertainment and under-reporting is likely. In the Netherlands, structural syndromic pneumonia surveillance is carried out using data extracted from electronic patient files maintained by sentinel GP practices, representing 7% of the Dutch population. Moreover, sentinel registration of pneumonia cases in nursing homes takes place. A separate virologic laboratory surveillance system provides information on circulating respiratory viruses. Since 2015, a pilot study has been carried out for hospitalized severe acute respiratory infections (SARI) patients. As it includes only two of 133 hospitals in the country at present, the obtained data is not yet reliable to provide early warning of infectious pneumonia outbreaks. Currently, no set threshold exists for unusual occurrence of pneumonia. Expert opinion determines which signals are discussed by the NEWC.
Emerging infectious diseases (EIDs) are “newly identified or known infectious diseases that have either expanded in geographic range or increased in infection prevalence over the previous two decades” (Liu and Yu 2017, 12). Some examples are the recent Ebola Virus Disease (EVD) in the West African countries of Guinea, Sierra Leone and Liberia, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) that has had large outbreaks in Saudi Arabia, United Arab Emirates, and the Republic of Korea, and Zika Virus Disease (ZVD) that affected many countries in the Americas and beyond.
Emerging infectious diseases pose serious public health concerns and cause major socio-economic consequences in affected persons and populations. The effects and impact of EIDs on individual and population health may vary from one individual to another and from one society to another. Globally, the distribution of EIDs vary between countries; as well as within each country. A strong health system is critical in effectively combating EIDs through the establishment of strong infection prevention and control programmes. Strong and resilient health systems better tackle these diseases and prevent them from assuming epidemic and pandemic levels.
Socio-economic, cultural and environmental conditions play a fundamental role in the emergence, spread and control/management of EIDs. In poor communities, a large part of the population live in overcrowded and squalid conditions. In these communities, mostly in the major cities of developing countries, there is a lack of clean drinking water, poor hygiene and sanitation. This environment creates opportunities for waterborne diseases and different forms of pollution. It is in the slums of the main cities of developing countries that most EIDs begin and spread and it is also in such areas of the cities that the greatest number of deaths are usually recorded. Infectious diseases like Ebola, HIV, TB, usually spread easily and widely from poor communities in emerging cities and through health workers who serve such communities. Hence, poverty creates a favourable condition for the spread of infectious diseases and makes it difficult for affected people to get adequate access to prevention and care (WHO 2012a, b). The journal of Infectious Disease of Poverty was launched in 2012 with the principal aim of fostering “interdisciplinary and transdisciplinary research that explicitly highlights the intersection of poverty and other ecological factors with disease” (Xia et al. 2013).
In this chapter, we critically examine the socio-economic and environmental factors that influence the emergence and spread of EIDs and discuss the ethical issues that arise from the global response and management of EIDs.
Emerging pathogens (EPs) are those characterized by the following pathways: 4) when a pathogen has undergone recent, rapid evolutionary change tantamount to speciation or strain differentiation, 5) when a pathogen is detected the human population for the first time, 6) when a pathogen significantly changes its pathology or clinical presentation, or 7) when a pathogen is discovered for the first time. Emerging pathogens are distinguished from the next stage, novel potential pathogens, in that there is clear evidence that they can cause disease in humans. Relative to emerging infectious diseases, however, emerging pathogens (in their present state) do not cause significant levels of morbidity or mortality. This is not to imply that they do not have the potential to become an emerging infectious disease; some will and some may never. In many cases emerging pathogens will have been identified as infectious in a single or small number of local cases. Examples of emerging pathogens include many multi-drug resistant microbes. For these pathogens, the potential health impact will vary with the availability and accessibility of treatment options. Another example of an emerging pathogen is Jamestown Canyon virus. Jamestown Canyon virus is a member of the California serogroup of bunyaviruses spread by mosquitoes from the typical cervid reservoir. Though this pathogen was originally discovered in the 1960s in mosquitoes, only 15 human cases have been reported in the United States since 2004. The Jamestown Canyon virus is rare, yet endemic in parts of the United States and Canada. Though it was newly discovered in the 1960s and now found to cause illness in humans, it is not increasing in incidence, impact, or geographic range. Therefore, Jamestown Canyon virus is an emerging pathogen that should be targeted for surveillance and prevention measures, but not for the wide-scale mitigation efforts an EID would require.
A strength of the Global Burden of Disease (GBD) project has been to insist that the number of deaths classified by primary (‘underlying’) cause adds up to the total number of deaths in the world each year. Coherent accounting has helped to eliminate duplications where, for example, deaths among TB cases that are also HIV-positive might have been counted as deaths from both TB and HIV/AIDS. The disadvantage, however, of assigning one death to one cause is that contributing causes of death may be overlooked. The interactions among contributing causes of death are potentially important in explaining epidemiological patterns—the distribution of cases and deaths by person, place and time—and therefore in devising methods for control.
For infectious diseases, whether exposure to a pathogen leads to the establishment of infection and to illness, and the outcome of a course of illness depend on the nature of the pathogen and associated risk factors. Some of these risk factors are chronic, non-infectious diseases. As attention in public health turns to the mounting burden of chronic diseases, greater visibility is being given to the biological interactions between the two groups, and to the opportunities to coordinate control efforts.
One example arises from the triangular relationship between nutrition, diabetes and TB. Under-nutrition increases the risk of TB by approximately 14% for every unit reduction in body mass index (BMI) (left side of the triangle in figure 4). Individuals with greater BMI are less likely to develop active TB, even to the point of obesity (base of triangle). But overweight is a risk factor for diabetes, which is also associated with a higher risk of TB (right side of triangle). The biological basis of these interactions is not fully understood. The implication, however, is that better nutrition and the management of diabetes could contribute to the prevention of TB. Reciprocally, the clinical management of TB presents an opportunity to identify people who are undernourished or who have diabetes. To illustrate, if the prevalence of diabetes in a population is 10% and the relative risk for TB among diabetics is 3, then the prevalence of diabetes among TB cases will be (0.1 × 3)/[1 + 0.1 × (3–1)] = 0.25. So, 25% of TB cases come from 10% of the population. The interaction is a chance to improve the efficiency of both infectious and non-infectious disease control programmes [41–43].
Diabetes and under-nutrition are just two among numerous risk factors for TB. In considering the best approach to TB control, their importance must be placed alongside other kinds of risk, for example over-crowded housing, the poor awareness of symptoms among patients, the lack of access to diagnostic and treatment facilities, the prohibitive cost of drugs to treat multidrug-resistant strains, medical malpractice, broken drug supply chains and patients not completing their treatment. Although these shortcomings are not usually thought to be risk factors, they account for a large proportion of the avertible burden of disease. On a post-2015 agenda for poverty reduction and sustainable development, infectious disease control will benefit from an approach that puts factors linked to physiology, health systems and environment together in a comprehensive, unified view of risk.
Because the prevalence of diabetes and Mycobacterium tuberculosis infection both increase with age, there is greater value in linking control efforts in ageing populations. Similarly, there is a growing number of older HIV-positive people on long-term antiretroviral treatment who have an elevated risk of metabolic, cardiac, renal, gastrointestinal, neurological and psychiatric diseases. Greater longevity also underlines the question of how to prevent cancers linked to infections that have been latent for years or decades, notably liver cancers associated with hepatitis B (preventable by vaccination) and hepatitis C viruses (treatable with drugs; see also §6).